Session IX: Immune Checkpoint Inhibitors for NSCLC

Moderator(s)

• 

  Corey Langer, MD, FACP

  Abramson Cancer Center, Hospital of the University of Pennsylvania

Presenter(s)

• 

  Leena Gandhi, MD, PhD

  Harvard Medical School/Dana-Farber Cancer Institute
• 

  Marina Garassino, MD

  University of Chicago
• 

  Edward Garon, MD, MS

  University of California, Los Angeles
• 

  Aaron Lisberg, MD

  University of California, Los Angeles

Presentations:

• 12:20 PM – 12:25 PM

  Welcome and Introduction; Pre-Session Audience Survey
  

  Co-Chair: Corey J. Langer, MD, FACP – Abramson Cancer Center, Hospital of the University of Pennsylvania
• 12:25 PM – 12:45 PM

  Basics of Immunotherapy in NSCLC
  

  Speaker: Edward B. Garon, MD, MS – University of California, Los Angeles
• 12:45 PM – 1:05 PM

  Primacy of CPIs in Front-Line Management
  

  Speaker: Marina Garassino, MD – University of Chicago
• 1:05 PM – 1:12 PM

  Debate: How to Handle PD-L1 > 50% - Use pembrolizumab + Histology Specific Chemo
  

  Debate Speaker: Aaron Lisberg, MD – University of California, Los Angeles
• 1:12 PM – 1:19 PM

  Debate: How to Handle PD-L1 > 50% - Use Pembrolizumab alone
  

  Debate Speaker: Edward B. Garon, MD, MS – University of California, Los Angeles
• 1:19 PM – 1:25 PM

  Debate: How to Handle PD-L1 > 50% - DISCUSSION
  

  Moderator: Corey J. Langer, MD, FACP – Abramson Cancer Center, Hospital of the University of Pennsylvania

  Panelist: Aaron Lisberg, MD – University of California, Los Angeles

  Panelist: Edward B. Garon, MD, MS – University of California, Los Angeles
• 1:25 PM – 1:32 PM

  Debate: 9LA/227/POSEIDON vs Pembro and Histology Specific Chem in <50% PDL1 - Histology Specific Chemo
  

  Debate Speaker: Leena Gandhi, MD, PhD – Harvard Medical School/Dana-Farber Cancer Institute
• 1:32 PM – 1:39 PM

  Debate: 9LA/227/POSEIDON vs Pembro and Histology Specific Chem in <50% PDL1 - 9LA/227/POSEIDON
  

  Debate Speaker: Marina Garassino, MD – University of Chicago
• 1:39 PM – 1:45 PM

  Debate: 9LA/227/POSEIDON vs Pembro and Histology Specific Chem in <50% PDL1 - DISCUSSION
  

  Moderator: Corey J. Langer, MD, FACP – Abramson Cancer Center, Hospital of the University of Pennsylvania

  Panelist: Leena Gandhi, MD, PhD – Harvard Medical School/Dana-Farber Cancer Institute

  Panelist: Marina Garassino, MD – University of Chicago
• 1:45 PM – 2:10 PM

  Q&A; Post-Session Audience Survey
  

  Moderator: Corey J. Langer, MD, FACP – Abramson Cancer Center, Hospital of the University of Pennsylvania

  Panelist: Leena Gandhi, MD, PhD – Harvard Medical School/Dana-Farber Cancer Institute

  Panelist: Marina Garassino, MD – University of Chicago

  Panelist: Edward B. Garon, MD, MS – University of California, Los Angeles

  Panelist: Aaron Lisberg, MD – University of California, Los Angeles